AGIO

Business Context and Reporting Period

Company: Agios Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period: Three and six months ended June 30, 2024
Business Overview: Agios is a biopharmaceutical company focused on cellular metabolism and rare diseases, particularly classical hematology. Its lead product, PYRUKYND® (mitapivat), is approved for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. The company is advancing clinical programs for thalassemia, sickle cell disease (SCD), and other indications, while developing novel candidates like AG-946 (tebapivat) and AG-181.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $1.9 million (28%) in Q2 and $4.5 million (36%) YTD compared to 2023, driven by increased sales of PYRUKYND®.
• Expense Increases: Total operating expenses rose by $14.0 million in Q2 and $18.1 million YTD.
  • R&D: Increased due to higher direct costs for the in-licensed siRNA TMPRSS6 program (polycythemia vera) and clinical trials for SCD, partially offset by lower costs for thalassemia trials.
  • SG&A: Increased due to commercial activities preparing for potential PYRUKYND® approval in thalassemia.
• Net Loss: Net loss widened by $12.3 million in Q2 and $12.8 million YTD, primarily due to increased operating expenses outpacing revenue growth.
• Liquidity: Cash and marketable securities decreased from $806.4 million at year-end 2023 to $645.3 million at June 30, 2024, reflecting operating cash burn of $172.5 million YTD.

Guidance, Outlook, and Risks

• Clinical Milestones:
  • Thalassemia: Aims to submit a supplemental New Drug Application (sNDA) to the FDA by the end of 2024 following positive Phase 3 data (ENERGIZE and ENERGIZE-T).
  • Sickle Cell Disease (SCD): Phase 3 enrollment expected to complete by end of 2024; topline data anticipated in 2025.
  • Pediatric PK Deficiency: ACTIVATE-kidsT primary endpoint was not met using Bayesian borrowing; detailed analysis pending. ACTIVATE-kids topline data expected in 2025.
  • AG-946 (LR MDS): Phase 2a achieved proof-of-concept; Phase 2b expected to initiate mid-2024.
• Contingent Payments (Vorasidenib):
  • Servier's NDA for vorasidenib has a PDUFA action date of August 20, 2024.
  • Agios has an agreement to sell Vorasidenib Royalty Rights to Royalty Pharma for $905.0 million, contingent on FDA approval by October 31, 2024.
  • Agios retains rights to a $200.0 million milestone payment and a 3% earn-out on sales exceeding $1.0 billion annually.
• Liquidity Outlook: Management expects current cash, cash equivalents, and marketable securities to fund operations for at least the next 12 months. Future funding may rely on PYRUKYND® sales, interest income, and contingent payments from the vorasidenib transaction.
• Risks: Key risks include failure to achieve regulatory approvals for new indications, inability to commercialize PYRUKYND® effectively, clinical trial failures, and the uncertainty of receiving contingent payments from Servier/Royalty Pharma.

Investor Verification Checklist

• Regulatory Timeline: Verify the August 20, 2024 PDUFA date for vorasidenib and the likelihood of the $905 million Royalty Pharma deal closing.
• Clinical Data: Review the detailed analysis of the ACTIVATE-kidsT trial results where the primary endpoint was not met under Bayesian borrowing.
• Commercial Execution: Monitor PYRUKYND® sales growth and market penetration in the U.S. for PK deficiency.
• Cash Burn Rate: Assess the sustainability of the ~$172 million operating cash burn over six months against the $645 million liquidity position.
• Pipeline Progress: Track the initiation of the AG-946 Phase 2b trial and the sNDA submission for thalassemia.